Home page

EXSCEL is a double-blind randomized, placebo controlled, multi-national superiority trial in patients with Type 2 Diabetes. It aims to compare the impact of including Exenatide as part of usual care versus usual care without Exenatide on major cardiovascular outcomes. A total of 9,500 patients will be recruited in around 30 countries across Australasia, Asia, Europe, North America and Latin America. They will be followed for a minimum of 4 years with the results expected in 2017.

The trial, which commenced in June 2010, is coordinated by the Duke Clinical Research Institute (DCRI) and the University of Oxford Diabetes Trial Unit (DTU).

• Co-Chair: Professor Robert Califf (Duke University, US)
• Co-Chair: Professor Rury Holman (The University of Oxford, UK)

• ClinicalTrials.gov Identifier: NCT01144338
• EudraCT No: 2010-021069-63

News

EXSCEL is funded by Amylin Pharmaceuticals in an academic collaboration with the Duke Clinical Research Institute and the Diabetes Trials Unit.

EXSCEL Study, Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857260     Fax: +44 (0)1865 857246     Email: exscel@dtu.ox.ac.uk

Home | Freedom of Information | Privacy Policy | Copyright | Accessibility | OCDEM | NDM | Oxford University